Stem Cell Therapy in Duchenne Muscular Dystrophy

Phase 1WithdrawnNCT02241434

Neurogen Brain and Spine Institute

Overview

The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Duchenne Muscular Dystrophy

Interventions

Stem CellBIOLOGICAL

Intrathecal autologous bone marrow mononuclear cell transplantation

Eligibility

Sex: ALLMin age: 3 YearsMax age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age group of 3-25 years * Duchenne muscular dystrophy diagnosed on the basis of clinical presentation Exclusion Criteria: * presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Locations (1)

Neurogen brain and spine institute

Navi Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Manual Muscle Testing

Time frame: 1 year

Secondary Outcomes

Brooke and Vignos Scale

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.